Cargando…
Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies
CONTEXT: The optimal management of oligometastatic prostate cancer (PCa) is still debated. OBJECTIVE: The purpose of the present systematic review and meta-analysis is to collect the available evidence to date to better define the role of stereotactic body radiotherapy (SBRT) in selected patients wi...
Autores principales: | Marvaso, Giulia, Volpe, Stefania, Pepa, Matteo, Augugliaro, Matteo, Corrao, Giulia, Biffi, Annalisa, Zaffaroni, Mattia, Bergamaschi, Luca, La Fauci, Francesco Maria, Mistretta, Francesco Alessandro, Luzzago, Stefano, Cattani, Federica, Musi, Gennaro, Petralia, Giuseppe, Pravettoni, Gabriella, De Cobelli, Ottavio, Orecchia, Roberto, Jereczek-Fossa, Barbara Alicja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317806/ https://www.ncbi.nlm.nih.gov/pubmed/34337513 http://dx.doi.org/10.1016/j.euros.2021.02.008 |
Ejemplares similares
-
Radioablation +/− hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159)
por: Marvaso, Giulia, et al.
Publicado: (2019) -
Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches
por: Marvaso, Giulia, et al.
Publicado: (2021) -
Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review
por: Corrao, Giulia, et al.
Publicado: (2021) -
Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer
por: Marvaso, Giulia, et al.
Publicado: (2022) -
Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome
por: Riva, Giulia, et al.
Publicado: (2017)